Erosive oesophagitis is a condition where the lining of the food pipe becomes inflamed and develops erosions due to repeated exposure to stomach acid. Managing this condition requires a combination of medications, lifestyle adjustments, and sometimes innovative treatments currently being tested in research studies. Understanding the available treatment options can help patients work with their doctors to find the best approach for healing the oesophagus and preventing future damage.

Understanding Treatment Goals for Erosive Oesophagitis

When someone is diagnosed with erosive oesophagitis, the main focus of treatment is to reduce symptoms, allow the damaged lining of the oesophagus to heal, and prevent the condition from coming back. The oesophagus, which is the tube that carries food from your mouth to your stomach, can become seriously damaged when stomach acid repeatedly flows backward into it. This backward flow is most commonly caused by a condition called gastroesophageal reflux disease, or GERD for short.^[3]

Treatment approaches depend on several factors including how severe the erosions are, what symptoms the patient is experiencing, and how well they respond to initial medications. Some people have mild erosions that heal quickly with treatment, while others have more advanced damage that requires stronger medications or even surgical procedures. The severity of erosive oesophagitis is often classified using a system called the Los Angeles grading system, which ranges from mild (Grade A) to severe (Grade D).^[7]

Medical societies and gastroenterology experts have established standard treatments that are proven to work for most patients. At the same time, researchers are actively studying new therapies in clinical trials to help patients who don’t respond well to standard treatments. Approximately 10 to 15 percent of patients with erosive oesophagitis experience what doctors call refractory disease, meaning their symptoms persist or their oesophagus doesn’t fully heal even after eight weeks of standard treatment.^[7][8]

The ultimate goal is not just to make symptoms disappear temporarily, but to heal the oesophagus completely and maintain that healing over time. Without proper ongoing treatment, the condition almost always returns, and repeated damage to the oesophagus can lead to serious complications such as narrowing of the food pipe, bleeding, or changes in the lining that may increase cancer risk.^[6]

Standard Treatment Approaches

Proton Pump Inhibitors: The Cornerstone of Treatment

The most effective medications for erosive oesophagitis are called proton pump inhibitors, commonly known as PPIs. These drugs work by blocking the production of stomach acid at its source—the proton pumps in the cells lining the stomach. When less acid is produced, there is less acidic material to flow backward into the oesophagus, giving the damaged tissue a chance to heal.^[3][8]

Common PPIs include omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole. These medications are available both over-the-counter at lower doses and by prescription at higher doses. Studies have shown that PPIs can heal erosive oesophagitis in 75 to 95 percent of patients after eight weeks of treatment, though symptom relief occurs in about 60 to 85 percent of cases.^[8][14]

For treating erosive oesophagitis, doctors typically prescribe higher doses than those used for simple heartburn. For example, omeprazole is often prescribed at 40 milligrams per day for erosive oesophagitis, which is double the standard dose approved for general GERD. The treatment usually lasts for four to eight weeks initially, though the exact duration depends on how quickly the oesophagus heals.^[3][13]

Research has shown that among the different PPIs, esomeprazole may provide slightly better healing outcomes compared to others. However, all PPIs in this class work similarly, and the choice often depends on factors such as insurance coverage, cost, and how well a patient tolerates a particular medication.^[14][19]

The effectiveness of PPIs does decrease in more severe cases of erosive oesophagitis. In patients with advanced disease classified as Los Angeles grades C or D, healing rates drop to about 60 to 70 percent. These patients may need longer treatment courses, higher doses, or additional therapies.^[14]

H2-Receptor Antagonists

Histamine-2 receptor antagonists, or H2RAs for short, are another type of acid-reducing medication. These include famotidine, cimetidine, and nizatidine. H2RAs work differently than PPIs—they block histamine from stimulating acid production in the stomach. While they can reduce acid, they are not as powerful or effective as PPIs for healing erosive oesophagitis.^[3][8]

In the past, H2RAs were commonly used as the first treatment for erosive oesophagitis. However, multiple studies comparing these medications to PPIs showed that PPIs are superior for both healing the oesophagus and maintaining that healing over time. As a result, current medical guidelines recommend PPIs as the preferred treatment, with H2RAs considered less effective for treating erosive oesophagitis.^[13][14]

Other Medications and Their Limited Role

Several other medications have been studied for erosive oesophagitis but have shown limited effectiveness compared to PPIs. Alginates are substances that form a protective barrier on top of stomach contents to prevent reflux. Sucralfate is a medication that coats and protects damaged tissue. Prokinetic agents are drugs that help speed up stomach emptying and strengthen the valve between the oesophagus and stomach. However, randomized controlled trials have found that these alternatives have limited healing ability for erosive oesophagitis compared to PPIs.^[14]

Traditional antacids containing calcium carbonate or magnesium hydroxide can provide quick, temporary relief of heartburn symptoms but do not heal erosive oesophagitis. These are sometimes used for on-demand relief of breakthrough symptoms in patients already taking PPIs.^[3]

Prokinetic agents deserve special mention because while they can help with symptoms related to poor stomach emptying like nausea and bloating, their long-term use is discouraged due to potential for serious or life-threatening complications. They are sometimes used short-term but are not recommended as primary treatment for erosive oesophagitis.^[3]

Possible Side Effects of Standard Treatments

While PPIs are generally considered safe for most people, long-term use has raised some concerns. Recent studies have examined potential risks including bone fractures, kidney problems, infections, and nutrient deficiencies. The 2022 guidelines from the American College of Gastroenterology acknowledge these concerns and recommend that doctors attempt to discontinue PPIs in patients who respond to an eight-week trial, though this may not be practical for those with erosive oesophagitis who need ongoing therapy to prevent recurrence.^[13]

Common side effects of PPIs can include headache, diarrhea, nausea, and abdominal pain. More serious but rare side effects include severe allergic reactions and a specific type of kidney inflammation. Patients taking PPIs long-term should have regular check-ups with their doctor to monitor for any problems.^[8]

Treatment Being Explored in Clinical Trials

Potassium-Competitive Acid Blockers: A New Class of Medication

One of the most promising developments in treating erosive oesophagitis is a newer class of medications called potassium-competitive acid blockers, or P-CABs. These drugs work differently than PPIs—they block acid production by competing with potassium at a different site in the acid-producing pump. This different mechanism may provide more complete and consistent acid suppression.^[3][8]

Vonoprazan is one P-CAB that has already been approved in several countries, though initially it was approved primarily for treating Helicobacter pylori infection in combination with antibiotics. Clinical trials have shown that vonoprazan is not inferior to standard PPIs like lansoprazole for both healing erosive oesophagitis and maintaining that healing over time. Importantly, vonoprazan appears to be particularly effective in patients with advanced erosive oesophagitis (Los Angeles grades C and D) where standard PPIs sometimes fall short.^[3][14]

In randomized comparative trials, vonoprazan has demonstrated healing rates that match or exceed those of PPIs. One significant advantage is that P-CABs may work better in patients who have been resistant to PPI therapy. The drug provides rapid and sustained acid suppression, which may translate to faster symptom relief for patients.^[14]

Another P-CAB called fexuprazan has been studied in clinical trials comparing it to esomeprazole. In these Phase III studies, fexuprazan was shown to be noninferior to esomeprazole in treating erosive oesophagitis. Researchers continue to study these medications to better understand their long-term safety profile and to determine which patients might benefit most from them.^[3]

Clinical trials for P-CABs typically involve patients with confirmed erosive oesophagitis of various grades of severity. Participants are usually adults who have not responded adequately to standard PPI therapy or who have advanced disease. These trials take place at medical centers in various locations including the United States, Europe, and Asia. Eligibility criteria typically include having active erosive oesophagitis confirmed by endoscopy and being old enough to consent to participate in research.^[8]

Novel Approaches and Combination Therapies

Researchers are exploring various combination approaches to help patients with difficult-to-treat erosive oesophagitis. Some studies are examining whether adding H2RAs at bedtime to daytime PPI therapy provides better acid control overnight, when breakthrough acid production can occur. This combination approach aims to provide 24-hour acid suppression.^[8]

Another medication called rebamipide, which works by protecting the mucosal lining and promoting healing, has been studied as a potential add-on therapy to PPIs. However, evidence for its effectiveness specifically in erosive oesophagitis remains limited compared to the proven benefits of PPIs and P-CABs.^[14]

Understanding Clinical Trial Phases

Clinical trials for new treatments of erosive oesophagitis generally progress through several phases. Phase I studies focus primarily on safety, testing new medications in small groups to determine safe dosing ranges and identify side effects. These initial studies help researchers understand how the human body processes the drug.^[2]

Phase II trials expand testing to larger groups of patients with erosive oesophagitis to evaluate whether the treatment is effective at healing the oesophagus and relieving symptoms. These studies also continue to assess safety and may test different doses to find the optimal amount. Phase II results provide preliminary evidence about whether a new treatment works well enough to justify larger studies.^[2]

Phase III studies are large randomized controlled trials that compare the new treatment directly to standard therapy, such as comparing a new P-CAB to an established PPI. These trials enroll hundreds or even thousands of patients and are designed to definitively prove whether the new treatment is as good as or better than existing options. Successful Phase III trials are necessary for regulatory approval of new medications.^[2]

Phase IV studies occur after a medication is approved and being used in regular clinical practice. These post-marketing studies monitor long-term effectiveness and safety in real-world settings with diverse patient populations.^[2]

Lifestyle and Dietary Modifications as Part of Treatment

While medications are essential for healing erosive oesophagitis, lifestyle and dietary changes play an important supporting role in treatment plans. These modifications can help reduce acid reflux and allow the oesophagus to heal more effectively.^[5]

Dietary changes focus on avoiding foods and beverages that trigger acid reflux or weaken the valve between the oesophagus and stomach. Common culprits include acidic foods like tomatoes and citrus fruits, spicy foods containing chili peppers, high-fat foods such as fried items and fatty meats, caffeinated beverages like coffee, carbonated drinks, chocolate, and peppermint. These foods can either increase acid production, relax the lower oesophageal sphincter, or directly irritate the damaged oesophageal lining.^[5][15]

Instead, patients are encouraged to eat foods that are less likely to trigger reflux, including low-acid fruits like bananas and melons, vegetables such as leafy greens and carrots, whole grains like oats and brown rice, lean proteins including skinless chicken and fish, and low-fat dairy alternatives. Eating smaller, more frequent meals rather than large meals can reduce pressure on the stomach and decrease the likelihood of reflux.^[5]

Timing of meals is also important. Patients should avoid lying down for at least two to three hours after eating, as gravity helps keep stomach contents from flowing backward into the oesophagus. Chewing food slowly and thoroughly aids digestion and may reduce reflux.^[15]

Beyond diet, several lifestyle modifications can significantly improve symptoms and healing. Elevating the head of the bed by six to eight inches using a wedge pillow or bed risers can prevent nighttime reflux. Maintaining a healthy weight is crucial because excess weight increases abdominal pressure, which pushes stomach contents upward. Even modest weight loss can lead to significant improvement in symptoms.^[5][15]

Smoking cessation is particularly important because smoking weakens the lower oesophageal sphincter and increases acid exposure. Similarly, alcohol should be avoided as it stimulates the oesophagus and increases acid production. Stress management through techniques like mindfulness, meditation, or yoga may also help reduce reflux symptoms, as stress can affect digestive function.^[15]

Wearing loose-fitting clothing around the abdomen is a simple change that can make a difference. Tight belts and constrictive garments increase abdominal pressure and can worsen reflux. Patients should also be aware that certain medications they take for other conditions, including nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, some antibiotics, and bisphosphonates for osteoporosis, can actually cause or worsen erosive oesophagitis.^[2][3]

When Surgery or Procedures Become Necessary

For some patients who do not respond adequately to medication even after trying different drugs and optimizing lifestyle factors, surgical or endoscopic procedures may be considered. Surgery is also an option for younger patients who face a lifetime of medication, those with difficulty adhering to daily medication, postmenopausal women concerned about osteoporosis from long-term PPI use, and those for whom the cost of ongoing medication is prohibitive.^[3][13]

The most common surgical procedure is called fundoplication, where the upper part of the stomach is wrapped around the lower oesophagus to strengthen the valve and prevent acid reflux. This procedure can be performed using minimally invasive laparoscopic techniques. While fundoplication can be effective at preventing reflux, it is a significant procedure that carries surgical risks and potential complications.^[13]

Various endoscopic therapies are also being developed and studied. These procedures are performed through an endoscope passed down the throat, avoiding the need for surgical incisions. Examples include techniques to tighten or modify the lower oesophageal sphincter, though these approaches are still being refined and are not yet as established as medication or surgery.^[7]

Most Common Treatment Methods

• Proton Pump Inhibitors (PPIs)
  • Block acid production in stomach cells, providing strongest acid suppression available
  • Include omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole
  • Heal erosive oesophagitis in 75-95% of patients after 8 weeks
  • Typically prescribed at doses higher than those used for simple heartburn
  • Require long-term maintenance therapy to prevent recurrence
• Potassium-Competitive Acid Blockers (P-CABs)
  • Newer class of acid-suppressing medications with different mechanism than PPIs
  • Include vonoprazan and fexuprazan being studied in clinical trials
  • Show effectiveness equal to or better than PPIs, especially in advanced disease
  • May work in patients who haven’t responded well to standard PPIs
  • Provide more complete and sustained acid suppression
• H2-Receptor Antagonists
  • Include famotidine, cimetidine, and nizatidine
  • Block histamine from stimulating acid production
  • Less effective than PPIs for healing erosive oesophagitis
  • Sometimes added to PPI therapy for nighttime acid control
• Lifestyle and Dietary Modifications
  • Avoiding trigger foods like acidic items, spicy foods, caffeine, and high-fat foods
  • Eating smaller, more frequent meals
  • Not lying down for 2-3 hours after eating
  • Elevating head of bed 6-8 inches during sleep
  • Maintaining healthy weight through balanced diet and exercise
  • Quitting smoking and avoiding alcohol
  • Wearing loose-fitting clothing around abdomen
• Surgical and Endoscopic Procedures
  • Fundoplication surgery wraps stomach around lower oesophagus to strengthen valve
  • Considered for patients not responding to medication or unable to take long-term drugs
  • Can be performed using minimally invasive laparoscopic techniques
  • Endoscopic therapies to modify lower oesophageal sphincter being developed